Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Paratek Pharmaceuticals Inc is a biotechnology business based in the US. Paratek Pharmaceuticals shares (PRTK) are listed on the NASDAQ and all prices are listed in US Dollars. Paratek Pharmaceuticals employs 207 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $1.96 |
|---|---|
| 52-week range | $1.60 - $7.02 |
| 50-day moving average | $2.04 |
| 200-day moving average | $3.64 |
| Wall St. target price | $18.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.18 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.96 from 2022-07-01
| 1 week (2022-06-27) | -4.85% |
|---|---|
| 1 month (2022-06-01) | 4.26% |
| 3 months (2022-04-01) | -33.33% |
| 6 months (2021-12-31) | N/A |
| 1 year (2021-07-02) | -71.76% |
|---|---|
| 2 years (2020-07-02) | -61.94% |
| 3 years (2019-07-03) | 4 |
| 5 years (2017-07-03) | 24.2 |
| Revenue TTM | $138.6 million |
|---|---|
| Gross profit TTM | $78.3 million |
| Return on assets TTM | -15.41% |
| Return on equity TTM | 0% |
| Profit margin | -42.32% |
| Book value | $-0.42 |
| Market capitalisation | $106.8 million |
TTM: trailing 12 months
We're not expecting Paratek Pharmaceuticals to pay a dividend over the next 12 months.
Paratek Pharmaceuticals's shares were split on a 1:12 basis on 30 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Paratek Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Paratek Pharmaceuticals shares which in turn could have impacted Paratek Pharmaceuticals's share price.
Over the last 12 months, Paratek Pharmaceuticals's shares have ranged in value from as little as $1.6 up to $7.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Paratek Pharmaceuticals's is 1.5749. This would suggest that Paratek Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co. , Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.